Company Overview
Snapshot
Founded in December 2024 by Eran Kotler, Avishai Gavish, and Mordechai Applebaum, Cellyrix Therapeutics operates with 1–10 employees. The company secured pre-seed funding in December 2024 from AION Labs.
Business overview
Cellyrix Therapeutics is a Health Tech & Life Sciences company focused on developing novel cancer treatments. Leveraging breakthroughs in single-cell sequencing and artificial intelligence, the company aims to understand and address tumor heterogeneity, which is a key factor in therapy resistance, metastasis, and relapse. Cellyrix operates in the Pharma & Medical Biotechnology sector, specifically in Drugs Discovery & Development, targeting the Life Sciences and Pharmaceutical industries with its B2B business model.
Log in to access full profile ›Company Intelligence Q&A
- When was Cellyrix Therapeutics founded?
- Cellyrix Therapeutics was founded in December 2024.
- Who are the founders of Cellyrix Therapeutics?
- The founders of Cellyrix Therapeutics are Eran Kotler, Avishai Gavish, and Mordechai Applebaum.
- What is Cellyrix Therapeutics' primary focus?
- Cellyrix Therapeutics focuses on introducing a new modality into cancer treatment by leveraging single-cell sequencing and artificial intelligence to address tumor heterogeneity.
- Which investor participated in Cellyrix Therapeutics' pre-seed funding round?
- In December 2024, Cellyrix Therapeutics received pre-seed funding from AION Labs.
- What technology does Cellyrix Therapeutics utilize in its approach?
- Cellyrix Therapeutics utilizes breakthroughs in single-cell sequencing and artificial intelligence to gain insights into intra-tumor heterogeneity and develop innovative cancer treatments.